Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
113,878,984
-
Share change
-
+116,328
-
Total reported value
-
$166,253,761
-
Put/Call ratio
-
23%
-
Price per share
-
$1.46
-
Number of holders
-
64
-
Value change
-
+$537,924
-
Number of buys
-
27
-
Number of sells
-
32
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q4 2022
As of 31 Dec 2022,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
64 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
113,878,984 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, BAILLIE GIFFORD & CO, NEA Management Company, LLC, BAKER BROS. ADVISORS LP, Long Focus Capital Management, LLC, PFM Health Sciences, LP, BANK OF AMERICA CORP /DE/, Rock Springs Capital Management LP, MORGAN STANLEY, and Endurant Capital Management LP.
This page lists
64
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.